Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 128

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study Comparing Setrusumab and Bisphosphonates for Children with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Neridronate Sodium
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Kite Pharma Inc.

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of Asciminib Treatment for Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.